Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

Literature DB >> 15539010

Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

Tracy A McGowan¹, Yanqing Zhu, Kumar Sharma.

Abstract

Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming growth factor-beta (TGF-beta) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-beta on matrix accumulation but have also found that blocking TGF-beta may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-beta in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2004 PMID： 15539010 DOI： 10.1007/s11892-004-0055-z

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

73 in total

Review 1. Interstitial pathomechanisms underlying progressive tubulointerstitial damage.

Authors: F Strutz; G A Müller
Journal: Kidney Blood Press Res Date: 1999 Impact factor: 2.687

2. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients.

Authors: M Taniyama; S Ohbayashi; M Narita; R Nakazawa; S Hasegawa; N Azuma; S Teraoka; K Ota; S Yamauchi; S B Margolin
Journal: Eur J Clin Pharmacol Date: 1997 Impact factor: 2.953

3. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.

Authors: Christine A Houlihan; Aysel Akdeniz; Con Tsalamandris; Mark E Cooper; George Jerums; Richard E Gilbert
Journal: Diabetes Care Date: 2002-06 Impact factor: 19.112

4. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Authors: Rajiv Agarwal; Senthuran Siva; Stephen R Dunn; Kumar Sharma
Journal: Am J Kidney Dis Date: 2002-03 Impact factor: 8.860

5. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells.

Authors: B L Riser; P Cortes; C Heilig; J Grondin; S Ladson-Wofford; D Patterson; R G Narins
Journal: Am J Pathol Date: 1996-06 Impact factor: 4.307

6. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.

Authors: Mohammed Ali Al-Bayati; Yan Xie; F Charles Mohr; Solomon B Margolin; Shri N Giri
Journal: Biochem Pharmacol Date: 2002-08-01 Impact factor: 5.858

7. The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus.

Authors: L Flores; M Vidal; J Abian; A Cases; J Ma Campistol; J Clària; S Lario; E Esmatjes
Journal: Diabet Med Date: 2004-03 Impact factor: 4.359

8. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Authors: W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Journal: Nature Date: 1992-11-26 Impact factor: 49.962

9. Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells.

Authors: Kumar Sharma; Leo Deelman; Muniswamy Madesh; Bernd Kurz; Emilio Ciccone; Senthuran Siva; Taishan Hu; Yanqing Zhu; Lewei Wang; Robert Henning; Xinliang Ma; Gyorgy Hajnoczky
Journal: Am J Physiol Renal Physiol Date: 2003-07-22

10. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats.

Authors: Annette J Dahly; Kimberly M Hoagland; Averia K Flasch; Sharda Jha; Steven R Ledbetter; Richard J Roman
Journal: Am J Physiol Regul Integr Comp Physiol Date: 2002-09 Impact factor: 3.619

11 in total

Review 1. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors: Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal: Nat Rev Nephrol Date: 2021-02-05 Impact factor: 28.314

Review 2. Diabetes and Kidney Disease: Role of Oxidative Stress.

Authors: Jay C Jha; Claudine Banal; Bryna S M Chow; Mark E Cooper; Karin Jandeleit-Dahm
Journal: Antioxid Redox Signal Date: 2016-04-01 Impact factor: 8.401

3. Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors: Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal: Int J Clin Exp Pathol Date: 2015-03-01

4. Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors: William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal: Open J Nephrol Date: 2012-06-25

5. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.

Authors: Hongyu Zhang; Viji Nair; Jharna Saha; Kevin B Atkins; Jeffrey B Hodgin; Thomas L Saunders; Martin G Myers; Thomas Werner; Matthias Kretzler; Frank C Brosius
Journal: Kidney Int Date: 2017-05-26 Impact factor: 10.612

6. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy.

Authors: Alexis Dixon; Corinne C Wells; Sandhya Singh; Regina Babayan; Christine Maric
Journal: Am J Nephrol Date: 2007-02-15 Impact factor: 3.754

10. Beneficial effect of traditional chinese medicinal formula danggui-shaoyao-san on advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats.

Authors: I-Min Liu; Thing-Fong Tzeng; Shorong-Shii Liou; Chia Ju Chang
Journal: Evid Based Complement Alternat Med Date: 2011-08-07 Impact factor: 2.629